Curated news and analysis on clinical trials, drug approvals, and medical research.
A secondary analysis of the Southwest Oncology Group S1609 trial found that larger baseline tumor burden correlated with shorter overall survival but not progression-free survival in rare cancer patients treated with nivolumab plus ipilimumab. The study of 722 patients showed tumor burden was independently associated with survival outcomes but not predictive of tumor regression after dual immunotherapy.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
The National Comprehensive Cancer Network has updated its bladder cancer guidelines to include ImmunityBio's Anktiva plus BCG for BCG-unresponsive papillary-only disease. The Category 2A recommendation expands treatment options beyond the drug's initial FDA approval for carcinoma in situ. ImmunityBio also announced its pivotal trial is adequately powered and European distribution partnerships to expand global access.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
A study published in The Lancet Digital Health reveals that after a stroke, the undamaged side of the brain appears structurally younger, suggesting active reorganization. Researchers analyzed over 500 stroke survivors using AI-driven brain scans, finding this 'contralesional shift' could lead to personalized rehabilitation strategies using brain age as a biomarker.
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
Bayer achieved its upgraded 2025 financial targets with group sales reaching 45.6 billion euros and projects solid 2026 performance. The company's pharmaceutical business shows rejuvenation with launch medicines becoming growth drivers, while Crop Science progresses in profitability improvement. Bayer continues strategic diversification in oncology and addresses litigation challenges while implementing cost-saving measures.
Priovant Therapeutics' brepocitinib demonstrated significant efficacy in the Phase 3 VALOR trial for dermatomyositis, meeting its primary endpoint with a 15.3-point greater improvement in Total Improvement Score versus placebo at Week 52. The treatment showed meaningful corticosteroid tapering and improvements across all nine key secondary endpoints, with benefits sustained through one year. Additional analyses revealed rapid itch reduction and improved skin-related quality of life in patients.
Doctors are implanting lab-grown stem cells into Parkinson's patients' brains in a groundbreaking clinical trial to restore dopamine production. The FDA has granted the Phase 1 REPLACE trial fast-track designation, testing iPSC-derived dopamine-producing cells in 12 patients with moderate to severe Parkinson's. Researchers will monitor participants for up to five years to assess motor function restoration and potential side effects.
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
Moderna shares declined nearly 6% amid extreme options market volatility and a new patent infringement lawsuit from BioNTech. The company faces significant financial challenges with negative earnings and declining revenue growth, while valuation metrics suggest potential overvaluation. Technical indicators point to bearish short-term momentum as the stock approaches key support levels.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The phase III TOP study shows osimertinib plus chemotherapy more than doubles progression-free survival to 34 months versus 15.6 months with osimertinib alone in EGFR/TP53 mutant NSCLC. The combination achieved an 82.9% response rate and represents a new strategy for this high-risk subgroup. Research continues into resistance mechanisms, including cancer-associated fibroblasts' role in promoting osimertinib resistance.
Prime Minister Mark Carney's Major Projects Office, created to fast-track nation-building infrastructure projects, has not accepted any projects six months after legislation passed. The program aims to reduce federal permitting from 7-10 years to two years but faces limitations with local review boards and Indigenous consent requirements.
